(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
(Washington, D.C.) — The Pennsylvania Auditor General’s report on Medicaid and pharmacy benefit managers (PBMs) is undermined by failing to note a simple, but key critical element: PBMs are reducing prescription drug costs and increasing access to needed treatments for
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
A recent paper from Dr. Casey Mulligan examines the services that PBMs provide, estimating they create $145 billion in value to society annually. This value translates into a 7:1 return on investment each year.
(Washington, D.C.) — As independent drugstore lobbyists descend on Harrisburg for their lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of Pennsylvania’s consumers and health plan sponsors by negotiating with drug manufacturers and
Pharmacy Benefit Managers reduce prescription drug costs for patients and use innovative technology to help patients get their prescriptions and lead healthier lives.
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
©2024 PCMA. All Rights Reserved.
